Engineered killer T cells could provide long-lasting immunity against cancer – Mirage News

UCLA Broad Stem Cell Research Center

Lili Yang

Theyve been called the special forces of the immune system: invariant natural killer T cells. Although there are relatively few of them in the body, they are more powerful than many other immune cells.

In experiments with mice, UCLA researchers have shown they can harness the power of iNKT cells to attack tumor cells and treat cancer. The new method, described in the journal Cell Stem Cell, suppressed the growth of multiple types of human tumors that had been transplanted into the animals.

Whats really exciting is that we can give this treatment just once and it increases the number of iNKT cells to levels that can fight cancer for the lifetime of the animal, said Lili Yang, a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA and the studys senior author.

Scientists have hypothesized that iNKT cells could be a useful weapon against cancer because it has been shown that they are capable of targeting many types of cancer at once a difference from most immune cells, which recognize and attack only one particular type of cancer cell at a time. But most people have very low quantities of iNKT cells; less than 0.1% of blood cells are iNKT cells in most cases.

Still, Yang and her colleagues knew that previous clinical studies have shown that cancer patients with naturally higher levels of iNKT cells generally live longer than those with lower levels of cells.

They are very powerful cells but theyre naturally present in such small numbers in the human blood that they usually cant make a therapeutic difference, said Yang, who also is a UCLA assistant professor of microbiology, immunology and molecular genetics and a member of the UCLA Jonsson Comprehensive Cancer Center.

The researchers goal was to create a therapy that would permanently boost the bodys ability to naturally produce more iNKT cells. They started with hematopoietic stem cells cells found in the bone marrow that can duplicate themselves and can become all types of blood and immune cells, including iNKT cells. The researchers genetically engineered the stem cells so that they were programmed to develop into iNKT cells.

They tested the resulting cells, called hematopoietic stem cell-engineered invariant natural killer T cells, or HSC-iNKT cells, on mice with both human bone marrow and human cancers either multiple myeloma (a blood cancer) or melanoma (a solid tumor cancer) and studied what happened to the mices immune systems, the cancers and the HSC-iNKT cells after they had integrated into the bone marrow.

They found that the stem cells differentiated normally into iNKT cells and continued to produce iNKT cells for the rest of the animals lives, which was generally about a year.

One advantage of this approach is that its a one-time cell therapy that can provide patients with a lifelong supply of iNKT cells, Yang said.

While mice without the engineered stem cell transplants had nearly undetectable levels of iNKT cells, in those that received engineered stem cell transplants, iNKT cells made up as much as 60% of the immune systems total T cell count. Plus, researchers found they could control those numbers by how they engineered the original hematopoietic stem cells.

Finally, the team found that in both multiple myeloma and melanoma, HSC-iNKT cells effectively suppressed tumor growth.

The studys co-first authors are Yanni Zhu, a UCLA project scientist, and Drake Smith, a UCLA doctoral student.

More work is needed to determine how HSC-iNKT cells might be useful for treating cancer in humans and whether increasing the number of HSC-iNKT cells could cause long-term side effects. But Yang said hematopoetic stem cells collected either from a person with cancer or a compatible donor could be used to engineer HSC-iNKT cells in the lab. The procedure for transplanting stem cells into patients bone marrow is already well-established as a treatment for many blood cancers.

Funding for the study was provided by the National Institutes of Health, the California Institute for Regenerative Medicine, the Concern Foundation, the STOP CANCER Foundation, a UCLA Broad Stem Cell Research Center Rose Hills Foundation Innovator Grant, and the centers training program, supported by the Sherry, Dave and Sheila Gold Foundation.

See the rest here:
Engineered killer T cells could provide long-lasting immunity against cancer - Mirage News

Anti-Aging Medicine Market Analysis, Growth by Top Companies, Trends by Types and Application, Forecast to2018 2026 – Analytics News

Longer life-expectancy is a cumulative effect of a healthy lifestyle and favorable environmental conditions. A trend of continuously increasing life expectancy has been a witness since a decade, primarily because of advances in medical sciences and treatment of chronic life-threatening diseases, availability of clean water and environment and other factors. This trend is projected to further show even more exponential growth graph owing to the anti-aging medicines, stem cell therapeutics, genetic screening and interventions, and high-tech biomedicines. American Academy of Anti-Aging Medicine claimed that anti-aging medicines can add up to 10-20 years to the life expectancy of a human. Today, a combination of calorie-restricted diet, regular exercise, and anti-aging medicines are claimed to slow the process of senescence and aging. Various medicines used against the treatment of acute or chronic diseases can be considered as anti-aging medicines, however, to define anti-aging medicine market we have considered only the drugs that are directly prescribed and used for delaying the effects of aging.

The constantly growing demand to look young in old individuals and to remain young and youthful in young people drive the anti-aging market. The influence of aesthetics from the fashion and television industry propel the demand to retain the features and energy of younger age in old people. Additionally, the increasing number of anti-aging medicine manufacturers in the decade contribute to higher availability of the anti-aging medicine resulting in expansion of the global anti-aging medicine market. However, skeptical approach to anti-aging medicine as being an external stimulator of cell-cycles is a restraint to the expansion of anti-aging medicine market.

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/26233?source=atm

The global Anti-aging medicine market is segmented on basis of product type, age group, distribution channel, and region: Based on the Product Type, the global anti-aging medicine market is segmented into the following: Hormone replacement therapy Immune enhancement therapy Antioxidant therapy Based on the route of administration, the global anti-aging medicine market is segmented into the following: Oral Injectable Topical Based on the Distribution Channel, the global anti-aging medicine market is segmented into the following: Hospital Pharmacies Retail Pharmacies E-commerce Drug Stores

The rising demand for beauty consciousness amongst people and the desire to stay young is the primary factor fueling the growth of anti-aging medicines in the market. The acclaimed benefits of the products and affordability along with regional presence compel the demand for anti-aging medicine in the global market. Hormonal replacement therapy segment in product type is expected to account maximum market share in the terms of revenue in the global anti-aging medicine market. However, antioxidant therapy segment in product type is expected to grow with the highest CAGR over the forecast years owing to the rising awareness about the plethora of benefits of antioxidants in anti-aging among the public. On the basis of the route of administration, the global anti-aging medicine market is segmented as oral, injectable and topical, out of which oral segment is expected to generate maximum revenue share over the forecast period. As per the distribution channel, the global anti-aging medicine market is segmented as hospital pharmacies, retail pharmacies, e-commerce, and drug stores. The e-commerce segment in the distribution channel is estimated to grow with the highest CAGR over the forecast time.

Regionally, the global anti-aging medicine market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America anti-aging medicine market is projected to account for the largest market share in the terms of revenue in the global anti-aging medicine market owing to the higher healthcare expenditure and presence of numerous manufacturers. Europe is expected to hold the second largest share in the global anti-aging medicine market during the forecast period because of the growing geriatric population and higher spending on healthcare products and supplements. MEA anti-aging medicine market is expected to witness sluggish growth over the forecast time owing to the limited presence of manufacturers and lower healthcare expenditure. Asia Pacific is projected to grow with the highest CAGR over the forecast years in the global anti-aging medicine market due to higher demand from end users and regional penetration of the key players in the region.

Request Report Methodology at https://www.persistencemarketresearch.com/methodology/26233?source=atm

Some of the players operating in the global anti-aging medicine market are Pfizer, Evolution GmbH, Himalaya Global Holdings Ltd., Cipla Limited, Mylan Laboratories, Novartis, Merck Group, Vitabiotics, William Ransom & Son Holdings Plc, Uni-Vite Healthcare and Health Made Easy Limited amongst others.

The report covers exhaustive analysis on: Anti-aging medicine Market Segments Anti-aging medicine Market Dynamics Historical Actual Market Size, 2013 2017 Anti-aging medicine Market Size & Forecast 2018 to 2026 Anti-aging medicine Market Current Trends/Issues/Challenges Competition & Companies involved Anti-aging medicine Market Drivers and Restraints

Regional Analysis: North America Latin America Europe Asia Pacific Middle East & Africa

Report Highlights: Shifting industry dynamics In-depth market segmentation Historical, current and projected industry size recent industry trends Key competition landscape Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards market performance

Request to view TOC at https://www.persistencemarketresearch.com/toc/26233?source=atm

Here is the original post:
Anti-Aging Medicine Market Analysis, Growth by Top Companies, Trends by Types and Application, Forecast to2018 2026 - Analytics News

New Progress in Stem-Cell-Free Regenerative Medicine

Regenerative medicine and stem cells are often uttered within the same breath, for good reason.

In animal models, stem cells have reliably reversed brain damage from Parkinsons disease, repaired severed spinal cords, or restored damaged tissue from diabetes, stroke, blood cancers, heart disease, or aging-related tissue damage. With the discovery of induced pluripotent stem cells (iPSCs), in which skin and other tissue can be reversed into a stem cell-like state, the cells have further been adapted into bio-ink for 3D printing brand new organs.

Yet stem cells are hard to procure, manufacture, and grow. And unless theyre made from the patients own cell supplymassively upping production coststheyre at risk of immune rejection or turning cancerous inside their new hosts.

Thinking outside the stem cell box, two teams have now explored alternative paths towards repairing damaged tissue, both inside and outside the body. The first, published in Nature, found that a tiny genetic drug fully restored heart function in a pig after an experimental heart attack.

Pig hearts are remarkably similar to human hearts in size, structure, and physiology, to the point that they may eventually become candidates for pig-to-human xenotransplants. Although itll take some time before we can proceed to clinical trials, said lead author Dr. Mauro Giacca from Kings College London, the drugthe first of its kindis a promising move towards repairing heart damage directly inside patients.

The second study, outlined in Nature Communications, explores a radically different approach that restores damaged lungs, which can then be used for tissue transplantation. To address the pressing need for donor lungs, Dr. Matt Bachetta at Vanderbilt University and colleagues from Columbia University developed a new protocol that not only keeps donor pig lungs alive, but also repairs any damage sustained during the extraction process so that the organs meet every single criterion for transplantation.

Video Credit: Brandon Guenthart/Columbia Engineering

Both ideas are universal in that they can potentially be expanded to other organs. Unlike stem cell treatments, theyre also one size fits all in that the therapies will likely benefit most patients without individual tailoring.

To be clear, Giaccas new treatment isnt gene therapy, in that it doesnt fundamentally change a hearts genetic code.

Rather, it relies on weird little RNA fragments called microRNAs. Similar to RNA, which carries genetic code from DNA to our cells protein-making factories, these molecules are made up of four genetic letters and flow freely inside a cell.

Averaging just 22 letters, microRNAs powerfully control gene expression in that they can shut down a gene without changing its genetic code. Scientists dont yet fully understand how microRNAs work. But humans have up to 600 different types of these regulators floating around our cells, and theyve been linked to everything from cancer and kidney problems to brain development, transgenerational inheritanceand yesheart disease.

These mysterious genetic drugs could meet a critical clinical need. Although modern medicine has ways to reduce damage from heart attacks, surviving patients still often retain permanent damage to the hearts structure, Giacca explained. Unlike skin or liver cells, mature heart cells are stoic little buggers in that they dont usually replenish themselves. This causes the heart to lose its ability to properly contract and pump blood, which eventually leads to heart failure.

Giaccas team decided to see if they could kick mature heart cells back into dividing action, rather than forming scar tissue. Using a high-volume screen, they first looked through miRNAs that can stimulate mature heart cells to divide after a heart attack in mice. One promising candidate emerged: hsa-miRNA-199a-3p (yeah, catchy, I know).

Next, the team used a virus to deliver the microRNA candidate into the hearts of 25 pigs, which were subjected to an experimental heart attack that blocked blood flow to the heart for 90 minutes. The miRNA, restricted to only the heart, immediately worked its magic and shut down several genetic pathways. Although the heart still retained damage, measured two days following the heart attack, within a month it reduced scar tissue by 50 percent. The treated hearts were also far stronger in their ability to contract compared to non-treated hearts, and grew slightly in muscle size.

Under the microscope, the team found that the miRNA forced mature heart cells back into a younger state. The cells regained their ability to divide and supplement damaged tissue. Its not an easy surgery: the team directly jabbed the heart 20 times with the virus to ensure that the organ evenly received the genetic drug.

The therapy also comes with a potentially troubling consequence. The team followed 10 pigs after the one-month mark. Although their heart functions readily improved, seven suddenly died from heart tremors within three to four weeks without any warning. Subsequent detective work revealed that it could be due to overgrowth of new heart cells. The treatment needs careful dosing, they concluded.

Despite these hiccups, the miRNA therapy is a welcome new addition to the heart regeneration family. It is a very exciting moment for the field. After so many unsuccessful attempts at regenerating the heart using stem cells, which all have failed so far, for the first time we see real cardiac repair in a large animal, said Giacca.

Bacchettas lung recovery team took a different approach. Rather than trying to directly repair lungs inside the body, they tackled another clinical problem: the lack of transplantable donor lungs.

Roughly 80 percent of donor lungs are too damaged for transplantation, said Bacchetta. Although there are many sources of trauma, including injuries from ventilators or fluid buildup inside the organ, the team focused on a major cause of damage: stomach contents.

Lungs are sensitive snowflakes. Theyre extremely easily scuffed up by stuff that comes out of our stomachs, such as food particles, bile, gastric juices, and enzymes. If youve ever had a horrific hangover over the toiletwell, you know it burns. Usually our lungs can heal; but in the case of transplantationright after deaththey often dont have the time to self-repair.

This lung shortage led Bacchettas team to look for alternative ideas. We were searching for a way to extend the ability to provide life-saving therapy to patients, he said, a search that took seven years of banging their heads against a wall.

Then came the winning lightbulb moment: if man-made devices arent enough to repair lungs outside the body, what about the eventual recipient? After all, lungs dont work alonethey thrive in a physiological milieu chock full of molecules that activate when the body senses injury.

I decided, look, weve got to use the whole body. The only way to do that was to use the potential donor recipient essentially as a bioreactor, said Bacchetta.

The team first poured gastric acid into the lungs of an unconscious donor pig to mimic injury. After six hours, they extracted the damaged lung and placed it carefully into a warm, humidified sterile bowlthe organ chamberand hooked the organ up to a ventilator. They then connected the lungs blood vessels to the recipients circulation. This essentially uses the recipient to help break down toxic molecules in the injured lungs while supplying them with fresh nutrients and healing factors.

It sounds pretty gruesome, but the trick worked. When supplemented with a wash that rinsed out stomach juices, the lungs regenerated in just three days. Compared to non-treated lungs, their functions improved six-fold. The technique restored and maintained the function of donor lungs for up to 36 hours, but Bacchetta expects to further expand the window to days or even weeks.

Our work has established a new benchmark in organ recovery, said Bacchetta. It has opened up new pathways for translational applications and basic science exploration.

Neither study is perfect, but they represent new pathways into regenerative medicine outside stem cells. And when it comes to saving lives, its never good to put all eggs inside one (stem cell) basket, especially when the need is large, pressing, and unmet.

Image Credit: sciencepics / Shutterstock.com

Read more here:
New Progress in Stem-Cell-Free Regenerative Medicine

The Stem Cell Theory of Cancer | Ludwig Center | Stanford …

Research has shown that cancer cells are not all the same. Within a malignant tumor or among the circulating cancerous cells of a leukemia, there can be a variety of types of cells. The stem cell theory of cancer proposes that among all cancerous cells, a few act as stem cells that reproduce themselves and sustain the cancer, much like normal stem cells normally renew and sustain our organs and tissues. In this view, cancer cells that are not stem cells can cause problems, but they cannot sustain an attack on our bodies over the long term.

The idea that cancer is primarily driven by a smaller population of stem cells has important implications. For instance, many new anti-cancer therapies are evaluated based on their ability to shrink tumors, but if the therapies are not killing the cancer stem cells, the tumor will soon grow back (often with a vexing resistance to the previously used therapy). An analogy would be a weeding technique that is evaluated based on how low it can chop the weed stalksbut no matter how low the weeks are cut, if the roots arent taken out, the weeds will just grow back.

Another important implication is that it is the cancer stem cells that give rise to metastases (when cancer travels from one part of the body to another) and can also act as a reservoir of cancer cells that may cause a relapse after surgery, radiation or chemotherapy has eliminated all observable signs of a cancer.

One component of the cancer stem cell theory concerns how cancers arise. In order for a cell to become cancerous, it must undergo a significant number of essential changes in the DNA sequences that regulate the cell. Conventional cancer theory is that any cell in the body can undergo these changes and become a cancerous outlaw. But researchers at the Ludwig Center observe that our normal stem cells are the only cells that reproduce themselves and are therefore around long enough to accumulate all the necessary changes to produce cancer. The theory, therefore, is that cancer stem cells arise out of normal stem cells or the precursor cells that normal stem cells produce.

Thus, another important implication of the cancer stem cell theory is that cancer stem cells are closely related to normal stem cells and will share many of the behaviors and features of those normal stem cells. The other cancer cells produced by cancer stem cells should follow many of the rules observed by daughter cells in normal tissues. Some researchers say that cancerous cells are like a caricature of normal cells: they display many of the same features as normal tissues, but in a distorted way. If this is true, then we can use what we know about normal stem cells to identify and attack cancer stem cells and the malignant cells they produce. One recent success illustrating this approach is research on anti-CD47 therapy.

Next Section >> Case Study: Leukemia

Excerpt from:
The Stem Cell Theory of Cancer | Ludwig Center | Stanford ...

10 talks on the future of stem cell medicine | TED Blog

Health TED Talks

Will the next generation think about diseases like Alzheimers and diabetes the way we think about polio and the whooping cough? Susan Solomon, the co-founder of the New York Stem Cell Foundation (NYSCF), certainly hopes so. In this fascinating talk from TEDGlobal 2012, Solomon delves into the foundations work on research with stem cells, which she calls the black boxes for diseases.

[Stem cells] are our bodies own repair kits. They are pluripotent, which means they can morph into all of the cells in our bodies, says Solomon. Right now there are some really extraordinary things that we are doing with stem cells that are completely changing the way we model disease, our ability to understand why we get sick and even develop drugs. But this field has been under siege, politically and financially.

While much of the fray is about embryonic stem cells still the gold standard when it comes to cells Solomon explains that another type of pluripotent stem cell (called iPS cells) can now be created by, essentially, reprogramming skin cells. These cells hold great promise for allowing researchers to see how diseases develop in humans, rather than in rodents.

Currently, developing a drug takes an average of 13 years, costs $4 billion, and has a 99% failure rate. And because its impossible to test a new drug on a large and representative sample of the human population, even a drug that tests well with many people will have side-effects for others, based on their genetic makeup. This is a problem thats sometimes not apparent until the drug is on the market and being prescribed to patients like in the tragic case of Vioxx.

Thats a terrible business model, but also is a horrible social model,she says. The way weve been developing drugs is essentially like going into a shoe store and no one asking what size you are They just say, Well, you have feet. Here are shoes.

From the TEDGlobal stage, Solomon outlined an exciting new approachher team at NYSCF has developed a machine that creates stem cell lines that, until now, had to be crafted by hand. NYSCF expects to produce 2,500 stem cell lines by the end of the year. The idea is to eventually produce a comprehensive array of 25,000 stem cell lines which act like avatars for a wide sample of people that researchers would have access to as they test new drugs.This could help avoid disasters and also let people know ahead of time of what side-effects they, specifically, can expect with a given medicine.

Two months after her talk, Solomon tells the TED Blog that interest in NYSCF work is growing. Pointing to a recent article in The New York Times about how future lung cancer treatments could be tailored to individuals, Solomon said, Its really the leading edge of where this field is going.

But Solomon stressed that it will be extremely difficult to change the current systems of drug development.

All the established companies have been using mouse-and-rodent testing forever, she said. A lot of peoples careers are staked to a method that is outdated. Its like the tech sector; this is really the high-tech sector for biomedical research.

To hear more about the NYSCF, watch Solomons talk. Below, watch 9 more talks about the incredible promise of stem cells.

Susan Lim: Transplant cells, not organsAs a woman, surgeon Susan Lim had to fight for the right to perform the first liver transplant in Asia. But she began to question the morality of such work given that with donor organs in such short supply many are coerced or forced to donate. Lim began looking at another approach: transplanting cells, rather than organs. In this talk, given at the INK Conference, she describes her work with adult stem cells derived from fat.

Daniel Kraft invents a better way to harvest bone marrowPediatrician and stem cell researcher Daniel Kraft has created a device to collect bone marrow in a way that is far less painful for both the patient and the doctor. In this talk from TED2009, Kraft shows how the stem cells found in this marrow could be used to treat heart disease and Parkinsons.

Eva Vertes: Do stem cells cause cancer?Microbiology prodigy Eva Vertes was 19 years old when she spoke at TED2005 about a theory that cancer might be a repair response to damaged stem cells in the lungs, liver, bones, etc. The implication she is testing? Its possible, although far-fetched, that in the future we could think of cancer being used as a therapy.

Alan Russell: The potential of regenerative medicineNot for the squeamish, in this talk from TED2006, medical futurist Alan Russell shows a video of stem cells being removed from a patients hip and injected directly into their heart and how this procedure has gotten much more precise over a short time. Such cell regeneration therapies will keep improving, Russell says.

Noel Bairey Merz: The single biggest health threat women faceWhile heart disease is often thought of as a male disease, Noel Bairey Merz explains that it is actually the biggest killer of women. In this talk from TEDxWomen 2011, Merz gives a call to arms for women to think of heart disease in the same way we do breast cancer, and talks about some exciting possibilities for treatment, including stem cell therapy.

Daniel Kraft: Medicines future? Theres an app for thatKraft, chair of the FutureMed program at Singularity University, talks about some of the big innovations coming down the pipeline in medicine. Near the end of this talk given at TEDxMaastricht, Kraft talks about cancer stem cells and how understanding them could lead to an era of personalized oncology the ability to leverage all of this data together, analyze the tumor and come up with a real, specific cocktail for the individual patient.

Juan Enriquez: The next species of humanFuturist Juan Enriquez believes that some big changes are coming, and that the next generation of humans could potentially be considered a different species. Why? In this talk from TED2009, he looks at the ability to engineer both cells and tissue, and describes some shocking ways researchers are using stem cells.

Kevin Stone: The bio-future of joint replacementArthritis affects more adults than cancer, says Kevin Stone in this talk from TED2010. While therapies using human tissue have been very promising in helping joint damage, there simply isnt enough donor tissue to go around. Stone explains a process which uses cartilage from a pig, loaded with a persons own stem cells, to ease pain and immobility.

Iain Hutchison: Saving facesIn this talk from TEDGlobal 2010 which contains some images of badly injured and disfigured faces that may be disturbing facial surgeon Iain Hutchison gives a look at his groundbreaking work. Towards the end of the talk, he describes an promising area of research tissue engineering which uses a patients own stem cells, taken from their hip, to help heal facial damage.

See the original post here:
10 talks on the future of stem cell medicine | TED Blog

Ansary Stem Cell Institute | Department of Medicine

Directed by Division Chief Dr. Shahin Rafii, the Ansary Stem Cell Institute is home to landmark advances in regenerative medicine.Dr. Shahin is nationally and internationally recognized for having pioneered the transformative paradigm demonstrating that tissue-specific adult endothelial cells (ECs) are unique instructive vascular niche cells that produce paracrine angiocrine factors to directly induce organ regeneration. This concept has revealed the remarkable heterogeneity of the adult vasculature that is underscored by production of tissue-specific angiocrine factors necessary for orchestrating organ regeneration. Under Dr. Rafiis direction, his laboratory has ushered in a new era in state-of-the-art models for the study of tissue-specific induction of angiocrine factors in ECs. His laboratory has driven many breakthroughs, including the identification of physiologically relevant tissue-specific stimulatory and anti-fibrotic angiocrine factors.The team utilizes in vivo genetic models to determine the role of angiocrine factors in organ regeneration and has played a major role in illuminating the intrinsic and microenvironmental determinants of vascular heterogeneity.

The Division of Regenerative Medicine also focuses on stem cell biology and their niches using mouse and human genetic models, tissue culture approaches and molecular biology to model the complex interactions between stem cells and their micro-environment. Multi-omics, molecular and cell biological techniques are combined to achieve a systems level understanding of these complex processes.

Our three investigators are engaging cutting edge technologies and concepts to decipher these interactions:

Shahin Rafiis Laboratory

Currently, Rafii's work is focused on identifying the molecular and cellular pathways involved in organ regeneration and tumor growth. He has established the concept that vascular endothelial cells are not just inert plumbing to deliver oxygen and nutrients, but also by production of tissue-specific growth factors, defined as angiocrine factors, support organ regeneration and tumor proliferation. He has shown that bone marrow endothelial cells by elaboration of angiocrine factors, such as Notch ligands, support stem cell self-renewal and differentiation into lymphoid and myeloid progenitors. He has recently demonstrated that liver and lung endothelial cells are endowed with unique phenotypic and functional attributes and by production of unique instructive growth factors contribute to the hepatic and alveolar regeneration.

He employed this knowledge to induce differentiation of the murine and human pluripotent embryonic stem cells into functional and engraftable vascular and hematopoietic derivatives. He developed screening approaches to exploit endothelial cells as a vascular niche platform to identify as yet unrecognized novel angiocrine factors that instruct organ morphogenesis as well as orchestrating stem cell self-renewal and differentiation.

Qiao Zhous Laboratory

The Zhou lab studies how specific cell types are created during development and uses this knowledge to regenerate or rejuvenate vital cells by in vivo reprogramming in adult organs. These adult cells demonstrate remarkable stability, maintaining their unique identity despite constantly changing physiological conditions. If this stability is undermined, diseases of metaplasia and cancer can arise. On the other hand, controlled manipulation of cell identity (converting a cell from one specialized type into another) is a key step towards tissue regeneration. Our laboratory investigates the molecular machinery that safeguards normal cell identity and seeks to control this process to regenerate tissues that are lost due to disease or injury.

Currently, two major model systems are employed. The first is revolved upon beta cells, the sole provider of insulin for the body. The goal is to regenerate beta cells in adults as a way to treat Type I diabetes, a disease marked by a lack of beta cells due to autoimmune attacks. In development is a novel approach to regenerate beta cells by converting cells of various internal organs, such as pancreatic exocrine cells, liver cells, and intestine cells, into beta cells by cellular reprogramming. The promise of this approach was recently demonstrated in animal models.

In process is the building of beta cells and spinal glial cells into platforms to understand the broad principles and molecular machinery that control cell identity. An array of molecular, cellular, and genetic techniques are employed in pursuit of this goal. These basic research efforts provide a firm foundation in our search for new treatments for degenerative diseases.

Raphael Liss Laboratory

Development and maintenance of the haematopoietic system relies on a scant number of self-renewing haematopoietic stem cells (HSCs) residing in the adult bone marrow and representing the top of a complex cellular hierarchy. Transplantation of HSCs, harvested from either bone marrow, mobilized peripheral blood or umbilical cord blood (UCB), has become the standard of care for numerous hereditary and malignant blood diseases. However, the limited availability of optimally human leukocyte antigen (HLA)- matched donor HSCs remains a challenge, especially for individuals of non-Caucasian background or mixed ethnicity. While the immunologic navet of UCB enables transplantation despite antigen mismatch, the relatively low HSC dose slows engraftment and raises the threat of graft failure.

In vitro expansion of UCB HSCs has been vigorously investigated, but despite substantial progress, current protocols are not yet clinically approved. Consequently, and because considerable interest in illuminating fundamental aspects of blood development, de novo generation of HSCs from non haematopoietic sources has become a major objective for the field, a holy grail, with wide-ranging implications for HSC biology and transplantation medicine.

This research has converted endothelial cells to engraftable HSC-like cells through direct conversion by expression of FOSB, GFI1, RUNX1, SPI1 (FGRS). Propagation of these cells onto a vascular-niche-like environment has substantially enhanced reprogramming efficiency, emphasizing the importance of inductive cues from the physiological micro-environment in the orchestration of haematopoietic specification. The converted cells acquired colony-forming potential and were successfully engrafted in recipient mice, after primary and secondary transplantation, producing long-term myeloid and B lymphoid progeny. This innovative approach constitute a landmark advance towards engineered autologous bone marrow transplant and hematological disease modeling.

Read this article:
Ansary Stem Cell Institute | Department of Medicine

PRP vs. Stem Cell Therapy in Medicine | NSI Stem Cell

We get it. Its confusing. So much is online, on TV, and in print about platelet rich plasma (PRP) and stem cell therapy in todays medical fields. How can the average person separate, to paraphrase author Nate Silver, the signal from the noise? Fact from hype? Which is better: platelet rich plasma treatments or therapies that are stem cell based? The short answer is: both! But there is a lot more to the story of PRP and stem cell therapy in regenerative medicine. NSI Stem Cell Centers in Florida use both types of therapy, because both have unique, remarkable qualities. Sometimes, only PRP treatment is used, as in certain physical injuries. Various types of knee pain, for example. Sometimes, only stem cell therapy is used, as in certain types of neurological conditions. But PRP and stem cell therapies are far from rivals. Often, they join forces to treat a wide array of diseases, injuries, and acute disorders. So, what are the differences between platelet rich plasma treatment and stem cell therapy in todays medicine? To answer that, lets take a closer look at each, and how the development of these regenerative techniques is revolutionizing medical practices across the board. Stem Cell Therapy In Practical Medicine Mesenchymal stem cells (MSCs) are known for their ability to self-renew and to differentiate into multiple lineage pathways. What does that mean? It means that MSCs are packets of potential. They remain in our bodies throughout life, waiting for chemical signals to alert them to the needs of both brain and body. In this service they can become whatever type of cell is needed for repair, re-growth, replacement, and regeneration. This includes cells of skin, bone, cartilage, blood, organs, and brain. It doesnt matter if the reason is disease, a wound, neurologically based, or even a combination of causes. Stem cell therapy in regenerative medicine is used to address and heal the underlying causes of illness and injury. There are various types of MSCs, classified according to where the body stores them. But the type that is responsible for the remarkable growth of stem cell therapy in todays practical medicine is the adipose-derived MSC. Also known as adipose stem cells, they are adult stem cells, meaning that they are among the types of MSCs that remain with us throughout life. The body stores adipose stem cells in the fatty tissue layer that lies just beneath the skin. This fatty tissue is called adipose fat. But why are adipose-derived MCSs in particular the driving force behind the explosive development of stem cell therapy in medicine? Adipose fat holds a particular abundance of MSCs. So, adipose-derived stem cells are easy to harvest. But they are also an exceptionally potent type of MSC. That means a smaller sample can be taken at harvest. Harvesting the sample is minimally invasive. This means that the procedure is far easier on the patient. The ease of the harvest and the potency of the adipose MSCs taken together have given rise to a golden age of stem cell therapy in regenerative medicine. Already over twenty treatments have been developed and are in practice as FDA guidelines-compliant procedures. They are available today across the United States at advanced medical clinics like NSI Stem Cell. As research and clinical trials continue to expand, more therapies come online regularly. Platelet Rich Plasma (PRP) In Practical Medicine Platelet rich plasma made its popular debut largely through professional sports. When well known athletes like basketball pro Brandon Roy, Masters champion golfer Tiger Woods, baseball star Alex Rodriguez, and tennis champion Rafael Nadal began using PRP to treat their career-related injuries, both the public and the wider medical community at large took note. Much of the present attention that PRP therapy has received from both the public and the medical community stems from pro athletes being treated for acute injuries related to their sports. These include ligament and muscle injuries. Prior to the development of PRP therapy, the treatment of such injuries relied on medication, physical therapy, or invasive surgery. But as more and more pro athletes began crediting platelet rich plasma with a quicker return to the game, PRP therapy began to be seen as a viable alternative to more invasive procedures. Whereas the source for stem cell therapy in todays fastest growing regenerative medicine procedures is adipose fat, platelet rich plasma is derived from the blood. As with adipose-derived MSC therapies, the blood sample does not have to be particularly large. After the sample is drawn, a portion of it undergoes a process call centrifugation. At the end of the process, the blood has been broken down into its three main components: platelet poor plasma (PPP), platelet rich plasma, and red blood cells. It is the platelet rich plasma that is the basis of all PRP therapies. The centrifugation separates the platelets from the other blood cells and increases their concentration. Then the increased concentration of platelets is combined with the remaining blood that was drawn. The platelets in PRP play a primary part in the clotting of blood. They are also a rich resource of growth factors. Growth factors play an essential role in wound healing and the process of regeneration. But PRP also releases an abundance of other substances critical in the healing of wounds. PRP augments the creation of blood vessels, improves healing of soft tissues, and enhances the regeneration of bone. Platelet rich plasma holds a concentration of platelets that is five to ten times the amount of platelets found in blood. Specifically, a platelet is a cell that is disk shaped. Along with red and white blood cells, platelets circulate through the bloodstream. A platelet contains natural growth factors. Among them are proteins and cytokines. When bones or soft tissue -such as tendons or ligaments- are damaged, the growth factors in platelets stimulate healing of bone and soft tissues. These proteins, cytokines and other growth factors in the PRP provide a number of ways to assist in the repairing of cell damage. They decrease inflammation, improve cell growth, and provide signaling to the immune system. In addition, particular types of cytokines focus on the creation of metabolic pathways that support cell recovery. PRP treatments are highly effective for relieving acute pain. The success of platelet rich plasma therapy is confirmed by both ultrasound and MRI images, which have shown definitive tissue repair after PRP therapy. PRP therapy is commonly used to address acute pain without resorting to invasive surgical techniques. In the FDA guidelines-compliant procedures practiced at NSI Stem Cell Centers, neither general anesthesia nor overnight hospital stays are necessary. There is also no prolonged recovery time. In general, most people return to their jobs or usual activities right after the procedure. As with FDA guidelines-compliant stem cell therapy in regenerative procedures, there is no risk of the patients immune system rejecting the therapy or any risk of disease transmission. This is because the PRP is made from the patients own blood. In both the case of PRP treatment and stem cell therapy in FDA guidelines-compliant procedures as practiced at NSI Stem Cell Centers, all are done on an out-patient basis. This is largely possible because of the ease of sample harvesting. With no need for highly invasive surgery or general anesthesia, overnight hospital stays are unnecessary. Neither is there any long, post-procedure recovery time involved. Patients can return to their usual, daily activities immediately. Examples of PRP and Stem Cell Therapies The list of illnesses, injuries, and conditions that are safely and effectively treated through PRP and/or stem cell therapy in regenerative medicine is already extensive. It includes: In addition, PRP and stem cells are often used as important enhancement aids in the traditional treatment of heart disease, liver disease, stroke, and traumatic brain injury. And great optimism grows among doctors regarding future stem cell therapy in the treatment of some of humankinds most pressing medical challenges, such as ALS and Alzheimers disease. What to Look for in a Stem Cell Medical Clinic When searching for a qualified stem cell therapy center its important to remember that not all of them are created equal. Stem cells, when used properly, are your bodys most powerful means for healing that can repair everything from ligaments, tendons, and cartilage to organs including your liver, pancreas and lungs and even neurological tissue like your brain, nerves and spinal cord. Unfortunately, the majority of so-called regenerative medicine clinics in the world arent trained in the latest, most technologically advanced procedures and will, therefore, provide poor results if any. The good news is the National Stem Cell Institute (NSI) has established the most advanced stem cell and platelet rich plasma procedures on the planet which has drawn patients from all over the world as well as professional athletes and celebrities because they are recognized as the best in the world at stem cell therapy. What makes NSI Stem Cell the top stem cell clinic in the world is demonstrated in 5 key areas: 1. Highly trained and experienced, board-certified doctors and team members who have performed stem cell procedures on thousands of patients with incredible results. 2. Cutting edge procedures utilizing all that regenerative medicine has to offer for many chronic degenerative conditions. 3. Leading scientific researchers who follow the advanced guidelines to maximize the healing potential of your stem cells and to maintain compliance and ethics 4. Use of only the most potent and viable resource of living, viable stem cells and harvested on the same day. No vial that you can purchase will contain living stem cells. If there is no harvest then there are no stem cells. 5. Post-operative guidance for supporting stem-cell growth including rehabilitation, diet and supplement protocols. NSI is a full-service healthcare center focused on patient outcomes. Stem cell therapy is only one tool used to help improve patients lives. Patients have raved about their experience at NSI Stem Cell Clinics testifying that it was their unique cutting-edge procedures that helped them experience a breakthrough when nothing else worked. If you want to learn more about NSI Stem Cell Clinics, you can set up a complimentary consultation today to see if you are a candidate. You can contact the National Stem Cell Institute at (877) 278-3623.

See the article here:
PRP vs. Stem Cell Therapy in Medicine | NSI Stem Cell

Top Stem Cell Conferences | Stem Cell Research 2019 …

Session and Tracks Track 1: Stem Cells Biology

Stem cells are defined as precursor cells that have the capability to self-renew and to come up with multiple mature cell types. Stem cells are an ongoing source of the differentiated cells that make up the tissues and organs of plants and animals. After collecting and culturing tissues is it possible to classify cells as per their operational concept. There are 2 major types of stem cells: Embryonic Stem Cells and Adult Stem Cells that is also known as tissue stem cells. This difficulty in characteristic stem cells in situ, without any manipulation, limits the understanding of their true nature. There is great interest in stem cells as a result of they have potential in the development of therapies for replacing defective or damaged cells ensuing from a variety of disorders and injuries, like Parkinson disease, heart disease, and diabetes.

Related Conferences:

25thGlobal Meet on Cancer Research & Oncology, May 20-21, 2019, Rome, Italy; 2ndWorld Congress on Advanced Cancer Science & Therapy, January 28-29, 2019, Dubai, UAE; 3rdAdvances in Cell & Stem Cell Research Congress, September 25-26, 2019, Rome, Italy; 3rdInternational Conference on Nanostructures, Nanomaterials and Nanoengineering, October 21-22, 2019, Las Vegas, USA; 3rdWorld Congress on Advanced Biomaterials and Tissue Engineering, August 26-27, 2019, Madrid, Spain;

Hematopoietic Stem Cells are the immature cell that is developed into all types of blood cells, including red blood cells, white blood cells, and platelets which are found in the peripheral blood and the bone marrow. These stem cells are also called blood stem cell. Studies have described two populations of Hematopoietic Stem Cells that are Long Term and Short Term. Long-Term Hematopoietic stem cells which are capable of self-renewal, while Short Term Hematopoietic stem cells do not have this capacity.

Related Conferences:

4thWorld Biotechnology Congress, May 20-21, 2019, London, UK; 6thWorld Congress on Microbial Biotechnology, June 17-18, 2019, Paris, France; Annual Congress on Advanced Tissue Science and Regenerative Medicine, April 15-16, 2019, Amsterdam, Netherlands; World Congress on Cell & Gene Therapy, September 25-26, 2019, Rome, Italy; World Congress on Novel Trends and Advances in Biotechnology, September 25-26, 2019, Rome, Italy;

Embryonic Stem Cells are developed when embryos formed during the blastocyst phase of embryological development. They can grow in all derivatives of the 3 primary germ layers i.e. ectoderm, endoderm and mesoderm. These include each of the more than 220 cell varieties within the adult body. Pluripotency distinguishes embryonic stem cells from adult stem cells found in adults; whereas embryonic stem cells can generate all cell types within the body, adult stem cells are multipotent and can produce only a restricted number of cell types. Embryonic stem cells are capable of propagating themselves indefinitely. This allows embryonic stem cells to be employed as useful tools for both research and regenerative medicine, because they can produce limitless numbers of themselves for continued research or clinical use.

Related Conferences:

25thGlobal Meet on Cancer Research & Oncology, May 20-21, 2019, Rome, Italy; 2ndWorld Congress on Advanced Cancer Science & Therapy, January 28-29, 2019, Dubai, UAE; 3rdAdvances in Cell & Stem Cell Research Congress, September 25-26, 2019, Rome, Italy; 3rdInternational Conference on Nanostructures, Nanomaterials and Nanoengineering, October 21-22, 2019, Las Vegas, USA; 3rdWorld Congress on Advanced Biomaterials and Tissue Engineering, August 26-27, 2019, Madrid, Spain;

Induced Pluripotent Stem Cells (iPSCs) are the adult stem cells derived from skin or blood cells which are reprogrammed to an embryonic stem cell maintaining the essential properties of introducing important genes and also to enables the development of an unlimited source of any type of human cell needed for the therapeutic purpose. Researchers have rapidly developed the techniques for generating iPSCs and by creating a new and powerful way to "de-differentiate" cells whose developmental fates.

Related Conferences:

4thWorld Biotechnology Congress, May 20-21, 2019, London, UK; 6thWorld Congress on Microbial Biotechnology, June 17-18, 2019, Paris, France; Annual Congress on Advanced Tissue Science and Regenerative Medicine, April 15-16, 2019, Amsterdam, Netherlands; World Congress on Cell & Gene Therapy, September 25-26, 2019, Rome, Italy; World Congress on Novel Trends and Advances in Biotechnology, September 25-26, 2019, Rome, Italy;

Though the concept of stem cell niche was prevailing in vertebrates, the first characterization of stem cell niche in vivo was figured out in drosophila germinal development. A stem-cell niche is an area of a tissue that provides a specific microenvironment, in which stem cells are present in an undifferentiated and self-renewable state. Cells of the stem-cell niche interact with the stem cells to take care of them or promote their differentiation. Characterization of these stem cell niches depends on the ability to identify stem cells in vivo in their normal setting. Through comparison of different stem cell systems, some themes emerge that indicate possible general characteristics of the relationship between stem cells and their supporting niche.

Related Conferences:

4thWorld Biotechnology Congress, May 20-21, 2019, London, UK; 6thWorld Congress on Microbial Biotechnology, June 17-18, 2019, Paris, France; Annual Congress on Advanced Tissue Science and Regenerative Medicine, April 15-16, 2019, Amsterdam, Netherlands; World Congress on Cell & Gene Therapy, September 25-26, 2019, Rome, Italy; World Congress on Novel Trends and Advances in Biotechnology, September 25-26, 2019, Rome, Italy;

Stem cell banking is the extraction, processing and storage of stem cells which can used for treatment when required. Stem cells have the amazing power to transform into any tissue or organ in the body. It is due to this unique characteristic that they have the potential to treat over 80 life threatening diseases, and provide numerous benefits to the baby, its siblings and the family. There are variety of sources from where stem cells can be banked, with the most common amongst them being the umbilical cord. Cord blood banking is that the extraction of stem cells from the umbilical cord. This is done during childbirth and is a fast, hassle free and painless procedure. While, the umbilical cord and cord blood are the foremost common sources of stem cells - the Placenta, amniotic sac and amniotic fluid are by far the richest sources, in terms of both - quantity and quality. Some other rich sources of stem cells are Placenta, Umbilical Cord, Amniotic Fluid, Dental Stem Cells, Menstrual Fluid, Adipose Tissue and Bone Marrow.

Related Conferences:

25thGlobal Meet on Cancer Research & Oncology, May 20-21, 2019, Rome, Italy; 2ndWorld Congress on Advanced Cancer Science & Therapy, January 28-29, 2019, Dubai, UAE; 3rdAdvances in Cell & Stem Cell Research Congress, September 25-26, 2019, Rome, Italy; 3rdInternational Conference on Nanostructures, Nanomaterials and Nanoengineering, October 21-22, 2019, Las Vegas, USA; 3rdWorld Congress on Advanced Biomaterials and Tissue Engineering, August 26-27, 2019, Madrid, Spain;

A procedure in which a patient receives healthy blood-forming cells (stem cells) to replace their own, when stem cells or bone marrow are damaged or destroyed by disease, as well as some types of cancer, or by high doses of chemotherapy or radiation therapy used to treat cancer. The healthy stem cells may come from the blood or from a donors bone marrow or from the umbilical cord blood of a newborn baby. A stem cell transplant may be autologous (use of stem cells from your own bone marrow or blood), allogeneic use of stem cells from someone else, the donor could also be a relative or somebody who isn't associated with you) or syngeneic (use of stem cells from an identical twin). The stem cells within the bone marrow transform into red blood cells, white blood cells and platelets. when these blood cells mature, they go into the peripheral blood (the blood that flows through the body). If the bone marrow is damaged or destroyed, it cant create normal blood cells. in a stem cell transplant, healthy stem cells are placed in your body to assist your bone marrow start to work properly. The new stem cells make healthy blood cells.

Related Conferences:

4thWorld Biotechnology Congress, May 20-21, 2019, London, UK; 6thWorld Congress on Microbial Biotechnology, June 17-18, 2019, Paris, France; Annual Congress on Advanced Tissue Science and Regenerative Medicine, April 15-16, 2019, Amsterdam, Netherlands; World Congress on Cell & Gene Therapy, September 25-26, 2019, Rome, Italy; World Congress on Novel Trends and Advances in Biotechnology, September 25-26, 2019, Rome, Italy;

Stem Cell Therapy is the treatment for various disorders which non-seriously life-threatening by using stem cells. These stem cells can be obtained from a lot of different sources and used to potentially treat more than 80 disorders which include neuromuscular, organ, chronic and degenerative disorders. Chronic disorders arise from degeneration or wear and tear of cartilage, muscle, bone, fat or the opposite organ, tissue or cell. This may occur owing to a spread of reasons, but it's usually the tactic spoken as aging, or 'getting old' that is the largest cause. Stem cell therapy is currently being researched for the treatment of various diseases. While research and clinical trials are in process with varying degrees of success, stem cell therapy holds the potential to offer a successful cure for these conditions.

Related Conferences:

4thWorld Biotechnology Congress, May 20-21, 2019, London, UK; 6thWorld Congress on Microbial Biotechnology, June 17-18, 2019, Paris, France; Annual Congress on Advanced Tissue Science and Regenerative Medicine, April 15-16, 2019, Amsterdam, Netherlands; World Congress on Cell & Gene Therapy, September 25-26, 2019, Rome, Italy; World Congress on Novel Trends and Advances in Biotechnology, September 25-26, 2019, Rome, Italy;

Cancer is defined as the abnormal growth of cells that possesses the ability to spread to other cells and tissues. Cancer is one of the major illness which it seemed to be more prevalent all over the world. Even though the death rate and peoples suffering from these diseases are in greater number in recent years. There are over 200 variety of types of cancer across the globe. The death rate increasing year-by-year due to this disease even in developed countries. Cancer Stem Cells (CSCs) are a small population of cells inside tumors with capabilities of self-renewal, differentiation, and tumorigenicity once transplanted into an animal host. The CSC hypothesis thus doesn't imply that cancer is always caused by stem cells or that the potential application of stem cells to treat conditions like cardiovascular disease or diabetes which is able to result in tumor formation. Rather, tumor-initiating cells possess stem-like characteristics to a degree sufficient to warrant the comparison with stem cells along with the observed experimental and clinical behaviors of metastatic cancer cells are extremely resembling the classical properties of stem cells

Related Conferences:

25thGlobal Meet on Cancer Research & Oncology, May 20-21, 2019, Rome, Italy; 2ndWorld Congress on Advanced Cancer Science & Therapy, January 28-29, 2019, Dubai, UAE; 3rdAdvances in Cell & Stem Cell Research Congress, September 25-26, 2019, Rome, Italy; 3rdInternational Conference on Nanostructures, Nanomaterials and Nanoengineering, October 21-22, 2019, Las Vegas, USA; 3rdWorld Congress on Advanced Biomaterials and Tissue Engineering, August 26-27, 2019, Madrid, Spain;

As an organism grows and develops, carefully orchestrated chemical reactions activate and deactivate components of the genome at strategic times and in specific locations. Epigenetics is that the study of these chemical reactions and the factors that influence them. It is strongly believed that there are some signals at the epigenetic level that regulate the fate of the stem cells. Though all of the cells in our body contain the same genetic makeup. These genes are not necessarily active at all times, rather they are expressed at times when needed in a highly controlled fashion.

Related Conferences:

25thGlobal Meet on Cancer Research & Oncology, May 20-21, 2019, Rome, Italy; 2ndWorld Congress on Advanced Cancer Science & Therapy, January 28-29, 2019, Dubai, UAE; 3rdAdvances in Cell & Stem Cell Research Congress, September 25-26, 2019, Rome, Italy; 3rdInternational Conference on Nanostructures, Nanomaterials and Nanoengineering, October 21-22, 2019, Las Vegas, USA; 3rdWorld Congress on Advanced Biomaterials and Tissue Engineering, August 26-27, 2019, Madrid, Spain;

Tissue Engineering is a scientific field centered on the advance of Tissue and Organ Substitutes by controlling their environment, biomechanical and biophysical parameters which include the utilization of a different or same scaffold for the arrangement of new tissue. These frameworks empower the In-vitro investigation of human physiology and physiopathology, while giving a rendezvous of biomedical instruments with potential materialness in toxicology, medicinal gadgets, tissue substitution, repair and Regenerative Medicine. Regeneration is that the progression of renewal, regeneration, and growth that makes it cells, organ regeneration to natural changes or events that cause damage or disturbance. This study is carried out as craniofacial tissue engineering, in-situ tissue regeneration, adipose-derived stem cells for tissue science which is also a breakthrough in cell culture technology. The study isn't stopped with the regeneration of tissue wherever it is further carried out in relation to cell signaling, morphogenetic proteins. Most of the neurological disorders occurred accidentally having a scope of recovery by replacement or repair of intervertebral discs repair, spinal fusion and plenty of more advancement.

Related Conferences:

4thWorld Biotechnology Congress, May 20-21, 2019, London, UK; 6thWorld Congress on Microbial Biotechnology, June 17-18, 2019, Paris, France; Annual Congress on Advanced Tissue Science and Regenerative Medicine, April 15-16, 2019, Amsterdam, Netherlands; World Congress on Cell & Gene Therapy, September 25-26, 2019, Rome, Italy; World Congress on Novel Trends and Advances in Biotechnology, September 25-26, 2019, Rome, Italy;

Regeneration Medicine is that the Survival of any living body essentially relying upon its capability to repair and recover injured or harmed tissues or potential organs amid its lifespan following injury, illness, or maturing. This will shape the system for recognizing novel clinical medicines which will enhance the mending and regenerative limit of individuals. The Regeneration process involves Cell Proliferation where most of the medical disorders occurred accidentally includes a scope of recovery by replacement or repair of intervertebral discs repair, spinal fusion and plenty of more advancements.

Related Conferences:

25thGlobal Meet on Cancer Research & Oncology, May 20-21, 2019, Rome, Italy; 2ndWorld Congress on Advanced Cancer Science & Therapy, January 28-29, 2019, Dubai, UAE; 3rdAdvances in Cell & Stem Cell Research Congress, September 25-26, 2019, Rome, Italy; 3rdInternational Conference on Nanostructures, Nanomaterials and Nanoengineering, October 21-22, 2019, Las Vegas, USA; 3rdWorld Congress on Advanced Biomaterials and Tissue Engineering, August 26-27, 2019, Madrid, Spain;

Cell reprogramming is the process of reverting mature, specialized cells into induced pluripotent stem cells. Reprogramming also refers to the erasure and re-establishment of epigenetic marks during mammalian germ cell development. The discovery of Induced pluripotent stem cells emphasizes on reprograming of any adult differentiated cells into stem cells by genetic modification under precisely controlled laboratory conditions. Reprograming of cells is supposed to presage revolution in both, medical and biological research and allows modeling and analysis of human diseases and cell cytotoxicity by drugs. The technique is still in its growing phase and requires a great deal of extensive research and approval from authorities for further trials.

Related Conferences:

25thGlobal Meet on Cancer Research & Oncology, May 20-21, 2019, Rome, Italy; 2ndWorld Congress on Advanced Cancer Science & Therapy, January 28-29, 2019, Dubai, UAE; 3rdAdvances in Cell & Stem Cell Research Congress, September 25-26, 2019, Rome, Italy; 3rdInternational Conference on Nanostructures, Nanomaterials and Nanoengineering, October 21-22, 2019, Las Vegas, USA; 3rdWorld Congress on Advanced Biomaterials and Tissue Engineering, August 26-27, 2019, Madrid, Spain;

Stem cell nanotechnology has emerged as a brand-new exciting field. Experimental and theoretical studies of interaction between nanostructures or nanomaterials and stem cells have made great advances. The importance of nanomaterials, nanostructures, and nanotechnology to the basic developments in stem cells-based therapies for injuries and degenerative diseases has been recognized. Apart from tracking the localization of stem cells, nanotechnology has improved targetability, half-life, and stability of stem cells by providing a suitable microenvironment. In particular nanomaterials have played a significant role in the isolation and proliferation or differentiation of stem cells and intracellular delivery of small and macromolecules within stem cells. In this field over the past few years, explore the application prospects, and discuss the issues, approaches and challenges, with the aim of rising application of nanotechnology in the stem cells research and development.

Related Conferences:

4thWorld Biotechnology Congress, May 20-21, 2019, London, UK; 6thWorld Congress on Microbial Biotechnology, June 17-18, 2019, Paris, France; Annual Congress on Advanced Tissue Science and Regenerative Medicine, April 15-16, 2019, Amsterdam, Netherlands; World Congress on Cell & Gene Therapy, September 25-26, 2019, Rome, Italy; World Congress on Novel Trends and Advances in Biotechnology, September 25-26, 2019, Rome, Italy;

Stem Cell Technologies will become a global biotechnology that manufactures, develops and sells product by providing the services to support academic and industrial scientists. Stem cells analysis and development team typically collaborates with educational institutes and industrial partners to manufacture, develop and distribute a specific product for a given analysis. A stem cell has helped several scientific communities and industries to develop technologies to achieving the world biotechnology market. The corporate makes a specialist in developing cell culture media, cell separation product, instruments and completely different reagents to be utilized in the cell, immunology, cancer, Regenerative medicine and cellular treatment analysis.

Related Conferences:

25thGlobal Meet on Cancer Research & Oncology, May 20-21, 2019, Rome, Italy; 2ndWorld Congress on Advanced Cancer Science & Therapy, January 28-29, 2019, Dubai, UAE; 3rdAdvances in Cell & Stem Cell Research Congress, September 25-26, 2019, Rome, Italy; 3rdInternational Conference on Nanostructures, Nanomaterials and Nanoengineering, October 21-22, 2019, Las Vegas, USA; 3rdWorld Congress on Advanced Biomaterials and Tissue Engineering, August 26-27, 2019, Madrid, Spain;

There are many research advancements and applications and of Stem Cells. Stem cell research that can be applied to develop new therapies includes cell replacement therapy, development of drugs, using iPSC technology to generate stem cells from the patients skin or blood, using trans differentiation technology to convert a specialized cell type to a progenitor cell and many more. It also carries the immense potential for treating a number of human diseases such as to repair or regenerate blood vessels, treatment of eyesight, Diabetes, Neurodegenerative Disorders and Wound Healing etc.

Related Conferences:

4thWorld Biotechnology Congress, May 20-21, 2019, London, UK; 6thWorld Congress on Microbial Biotechnology, June 17-18, 2019, Paris, France; Annual Congress on Advanced Tissue Science and Regenerative Medicine, April 15-16, 2019, Amsterdam, Netherlands; World Congress on Cell & Gene Therapy, September 25-26, 2019, Rome, Italy; World Congress on Novel Trends and Advances in Biotechnology, September 25-26, 2019, Rome, Italy;

Carefully planned and ethically approved clinical trials resulting from a robust preclinical pathway are necessary to advance the field. This will require a programmatic approach that involves partnerships of clinicians, academics, industry, and regulatory authorities with a focus on understanding basic biology that informs a tight linkage between preclinical and clinical studies. Rather than suggesting that clinical trials are premature, such trials should be encouraged as part of multidisciplinary programs in regenerative medicine.

Related Conferences:

25thGlobal Meet on Cancer Research & Oncology, May 20-21, 2019, Rome, Italy; 2ndWorld Congress on Advanced Cancer Science & Therapy, January 28-29, 2019, Dubai, UAE; 3rdAdvances in Cell & Stem Cell Research Congress, September 25-26, 2019, Rome, Italy; 3rdInternational Conference on Nanostructures, Nanomaterials and Nanoengineering, October 21-22, 2019, Las Vegas, USA; 3rdWorld Congress on Advanced Biomaterials and Tissue Engineering, August 26-27, 2019, Madrid, Spain;

The field of bioethics has addressed a broad swathe of human inquiry, ranging from debates over the boundaries of life, surrogacy, and the allocation of scarce health care resources to the right to refuse medical care for religious or cultural reasons. StemGen is a research database of international, regional and national normative instruments concerning the socio-ethical and legal aspects of stem cell research and related therapies. The regulation of stem cell research is an issue that has drawn much comment, criticism and even judicial arbitration in recent years along with the marketing status of Stem Cells, Cell therapy, Regenerative Medicine, Tissue Engineering and many more worldwide.

Related Conferences:

4thWorld Biotechnology Congress, May 20-21, 2019, London, UK; 6thWorld Congress on Microbial Biotechnology, June 17-18, 2019, Paris, France; Annual Congress on Advanced Tissue Science and Regenerative Medicine, April 15-16, 2019, Amsterdam, Netherlands; World Congress on Cell & Gene Therapy, September 25-26, 2019, Rome, Italy; World Congress on Novel Trends and Advances in Biotechnology, September 25-26, 2019, Rome, Italy;

See the original post:
Top Stem Cell Conferences | Stem Cell Research 2019 ...

Bone Marrow & Stem Cell Transplant | Weill Cornell Medicine

Bone Marrow & Stem Cell Transplant

The Bone Marrow and Stem Cell Transplant Program at Weill Cornell Medicine was established with the mission of providing the best care and most innovative research in a compassionate and comfortable environment.

We take a multidisciplinary approach to care for patients with cancer and blood diseases who need stem cell transplants, providing world-class clinical care in collaboration with experts in leukemia, lymphoma, myeloma and other blood disorders. Based at NewYork-Presbyterian/Weill Cornell Medical Center, one of the top ten general hospitals in the nation, the expertise of our consulting team is unsurpassed.

Our patients and families cope with life-threatening illness; as such, sensitivity and compassion are a priority for our team. We view each patient as an individual, and our approach ensures that each treatment regimen is narrowly tailored to meet the unique, changing needs of our patients and their families before, during and after transplant.

As New Yorks premier healthcare institution, Weill Cornell Medicine is at the forefront of scientific research and clinical trials, enabling us to provide a full range of diagnostic and treatment protocols, including the latest breakthroughs in medicine.

Our Team

Our team of internationally-recognized bone marrow transplant and stem cell surgery specialists is known for advanced work and published research in:

Treating patients with aggressive leukemia and myelodysplastic syndromes

Bridge protocols for patients with refractory lymphoma and leukemia

Novel strategies to mobilize stem cells and improve transplantation for patients with multiple myeloma, leukemia and lymphoma

Transplants for solid tumors, severe auto-immune disorders, and AIDS

Treatment

We pride ourselves on exceptional outcomes and offer patients the most advanced diagnostic methods and treatment therapies to improve quality of life, including:

Umbilical cord blood transplant

Outpatient transplant

Autologous stem cell transplant; uses stem cells extracted from the bone marrow or peripheral blood of the patients own blood

Allogeneic stem cell transplant; uses stem cells extracted from the bone marrow or peripheral blood of a matching donor

Hematopoietic stem cell transplant; used to treat certain cancers of the blood/bone marrow, including leukemia and myeloma

Matched unrelated donor stem cell transplantation through the National Donor Matching Program

Non-ablative "mini" transplants

Haplo-Cord Transplant, allowing us to find donors for all patients, regardless of age or ethnic background

Bendamustine, a therapy that is well-tolerated and has excellent response rates in patients with myeloma

Novel forms of transplant, offering hope and success to older patients with leukemia

Clinical Trials

Clinical trials are important to improve outcomes and offer new treatment options. At Weill Cornell Medicine, we conduct more studies in blood cancers than any of our regional peers, allowing us to provide our patients with access to many multi-phase clinical trials. As active members of the international cancer research community, our oncologists also collaborate with other research centers to offer patients the most promising treatments available.

Second Opinions

In concert with your referring physician, we are always available to offer a second opinion in the form of a consultation with one of our specialists.

Why Choose Us?

Our collaborative approach means our patients receive supportive, comprehensive care and the most cutting-edge stem cell therapy and treatments. This enables patients to receive the best possible transplant outcomes. Additionally, we offer more allogeneic stem cell transplants for older adults than any other center in New York City and the entire tri-state area.

For more information or to schedule an appointment, call us at 212-746-2119 or 212-746-2646.

Located in New York City, Weill Cornell Medical College is ranked among the nations best by U.S. News & World Report year after year.

Read the original here:
Bone Marrow & Stem Cell Transplant | Weill Cornell Medicine

Stem Cell | Regenerative medicine | 2019 | Conference …

Responsibility

The organizers holds no responsibilities or liabilities of the personal articles of attendees at the venue against any kind of theft, lost, damage, due to any reason whatsoever. Delegates are entirely responsible for the safety of their own belongings.

Insurance

No insurance, of any kind, is included along with the registration in any of the events of the organization.

Transportation

Please note that transportation and parking is the responsibility of the registrant, Allied Academies will not be liable for any actions howsoever related to transportation and parking.

Press/Media

Press permission must be obtained from Allied Academies Conference Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies is an objective third-party nonprofit organization and this conference is not associated with any commercial meeting company.

Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference after payment of complete registration fee. Once registration is complete, please contactstemcell@alliedevents.org

Cancellation Policy

All cancellations or modifications of registration must be made in writing to finance@alliedacademies.com

If, due to any reason, Allied academies postpone an event on the scheduled date, the participant is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within period of one year from the date of rescheduling.

Postponement of event

If, due to any reason, Allied academies postpone an event and the participant is unable or unwilling to attend the conference on rescheduled dates, he/she is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within period of one year from the date of rescheduling.

Transfer of registration

All registrations, after payment of complete registration fee, are transferable to other persons from the same organization, if in case the person is unable to attend the event. Request for transfer of registration must be made by the registered person in writing to contacts@alliedacademies.com Details must include the full name of replaced new registrant, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified. Registration can be transferred to one conference to another conference of Allied academies if the person is unable to attend one of conferences.

However, Registration cannot be transferred if intimated within 14 days of respective conference.

The transferred registrations will not be eligible for Refund.

This cancellation policy was last updated on April 04, 2015.

Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues are not covered under the cancellation policy of Allied academies, including the inability to obtain a visa.

Refund Policy.

If the registrant is unable to attend, and is not in a position to transfer his/her participation to another person or event, then the following refund policies apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overhead charges, following Refund Policy

Orders are available:

Accommodation Cancellation Policy

Accommodation Service Providers (Hotels) have their own cancellation policies which are applicable when cancellations are made less than 30 days prior to arrival. If in case the registrant wishes to cancel or amend the accommodation, he/ she is expected to inform the organizing authorities on a prior basis. Allied academies will advise the registrant to ensure complete awareness about the cancellation policy of your accommodation provider, prior to cancellation or modification of their booking.

Visit link:
Stem Cell | Regenerative medicine | 2019 | Conference ...